STOCK TITAN

Insider for issuer (NASDAQ: VRTX) plans sale of 466 common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ourania Tatsis has filed a Form 144 to sell 466 shares of common stock. The shares were acquired through restricted stock vesting on 02/10/2026 as compensation and are planned to be sold around 02/11/2026 through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $214,560.38.

In the prior three months, Tatsis sold 4,500 common shares on 12/03/2025 for gross proceeds of $2,024,955.40 and another 4,500 shares on 01/07/2026 for $2,137,455.00.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the VRTX Form 144 filing for Ourania Tatsis disclose?

The filing discloses that Ourania Tatsis plans to sell 466 common shares under Rule 144. It provides details on how the shares were acquired, planned sale timing, market value, broker, and recent historical share sales over the last three months.

How many VRTX shares is Ourania Tatsis planning to sell under this Form 144?

The notice states that 466 shares of common stock are planned for sale. These shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 02/11/2026 and an aggregate market value listed as $214,560.38.

How did Ourania Tatsis acquire the 466 VRTX shares to be sold?

The 466 common shares were acquired on 02/10/2026 through restricted stock vesting. The filing identifies the issuer as the source of the shares and classifies the nature of payment as compensation, meaning the shares were awarded rather than bought for cash.

What is the aggregate market value of the VRTX shares in this planned sale?

The Form 144 lists an aggregate market value of $214,560.38 for the 466 common shares to be sold. This value reflects the market price used in the filing and helps indicate the dollar size of the planned transaction at the time of the notice.

Which broker and exchange are involved in the VRTX Form 144 sale by Ourania Tatsis?

The filing shows Fidelity Brokerage Services LLC as the broker handling the trade. The common shares are planned to be sold on NASDAQ, with the approximate date of sale given as 02/11/2026 in the securities information section.

What VRTX share sales has Ourania Tatsis made in the past three months?

The document reports that 4,500 common shares were sold on 12/03/2025 for gross proceeds of $2,024,955.40, and another 4,500 shares on 01/07/2026 for $2,137,455.00, showing recent sizable insider sales before this new planned transaction.

How many VRTX shares are outstanding as referenced in this Form 144?

The securities information section lists 253,718,831 shares outstanding of the issuer’s common stock. This figure provides context for the company’s total equity base relative to the 466-share sale planned by Ourania Tatsis in this notice.
Vertex Pharmaceuticals Inc

NASDAQ:VRTX

VRTX Rankings

VRTX Latest News

VRTX Latest SEC Filings

VRTX Stock Data

117.59B
253.12M
0.14%
98.18%
1.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON